MDT-AP-1245
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 42.96
- os_event
- false
- age_years
- 3.92
- sex
- M
- new_clusters
- C2
- umap1_2d
- 1.937383198
- umap2_2d
- 0.144278772
- umap1_3d
- -0.78144359
- umap2_3d
- -1.794967844
- umap3_3d
- -0.264708813
- dataset
- Med-Taylor
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0QYS36NR | Ependymoma NOS | — | 0.909 |
| 2 | BS_KXMYBQ6N | EPN | EPN Tumor | 0.909 |
| 3 | SRR11296840 | — | — | 0.905 |
| 4 | BS_0QYS36NR | EPN | EPN Tumor | 0.900 |
| 5 | SJEPD001508_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.890 |
| 6 | MDT-AP-0821 | Med | Medulloblastoma | 0.886 |
| 7 | BS_KXMYBQ6N | Spinal Cord Ependymoma | — | 0.884 |
| 8 | BS_4T0HPZDC | Posterior Fossa Ependymoma | — | 0.882 |
| 9 | BS_X23724NJ | high-grade glioma | — | 0.879 |
| 10 | BS_TK84K675 | high-grade glioma | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |